There was a section on this in this week's Economist: genetic sequencing is quickly becoming cheaper and more informative. In the near future we may be able to tell accurately how much risk there is for an individual to get Alzheimer's, breast cancer, type II diabetes and other diseases, as well as how they respond to some treatments.
Should this information be available to insurance companies? On the one side there are fears that companies will shoot up their rates for certain customers so that said customers can't afford health care. On the other, there's the possibility that customers will get a cheap sequencing, determine their vulnerabilities, and order exactly what they need. That sounds good, but if only one side can play that game it could bring the insurance industry crashing down; their profit margins depend on playing the odds. And some people argue that genetic profiles aren't in principle different from family history, cholesterol levels or other risk indicators used by companies to calculate premiums; genetic profiles are just more accurate.
So, what do you think?
Should this information be available to insurance companies? On the one side there are fears that companies will shoot up their rates for certain customers so that said customers can't afford health care. On the other, there's the possibility that customers will get a cheap sequencing, determine their vulnerabilities, and order exactly what they need. That sounds good, but if only one side can play that game it could bring the insurance industry crashing down; their profit margins depend on playing the odds. And some people argue that genetic profiles aren't in principle different from family history, cholesterol levels or other risk indicators used by companies to calculate premiums; genetic profiles are just more accurate.
So, what do you think?
Comment